Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999–2007: Results of EUROCARE-5

Lepage, Côme; Capocaccia, Riccardo; Hackl, Monika; Lemmens, V.; Molina, Esther; Pierannunzio, Daniela; Sant, Milena; Trama, Annalisa; Faivre, Jean

doi:10.1016/j.ejca.2015.07.034

Cited by 129 publications

(114 citation statements)

References 24 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have established that Smad4 may interact with other signaling pathways, including Notch and MAPK, and function independently of TGF-β (20). Despite clear evidence of the association between Smad4 and pancreatic cancer (1,(4)(5)(6), the mechanism of the cross-talk between Smad4 and other signaling pathways that affect the development of pancreatic cancer remains unclear. JNK activity is reported to be pivotal in tumor development, particularly in gastrointestinal tumors, including hepatocellular carcinoma (12), colon cancer (26) and pancreatic cancer (27).…”

Section: Discussionmentioning

confidence: 91%

“…Elucidating the molecular mechanisms of pancreatic cancer may contribute to the early diagnosis and effective therapies for patients with pancreatic cancer. It has been demonstrated that Smad4 deletions are associated with pancreatic cancer metastasis, and Smad4 gene mutations are associated with poor prognosis in pancreatic cancer (1,2). Previous studies have established that Smad4 may interact with other signaling pathways, including Notch and MAPK, and function independently of TGF-β (20).…”

Section: Discussionmentioning

confidence: 99%

“…Pancreatic cancer is a devastating disease with an extremely poor prognosis, and patients often do not undergo curative surgery (1). Additionally, effective chemotherapy and radiotherapy treatments for pancreatic cancer are limited (1).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Smad4 inhibits cell migration via suppression of JNK activity in human pancreatic carcinoma PANC-1 cells

Zhang¹,

Cao²,

Pei³

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Smad4 is a common Smad and is a key downstream regulator of the transforming growth factor-β signaling pathway, in which Smad4 often acts as a potent tumor suppressor and functions in a highly context-dependent manner, particularly in pancreatic cancer. However, little is known regarding whether Smad4 regulates other signaling pathways involved in pancreatic cancer. The present study demonstrated that Smad4 downregulates c-Jun N-terminal kinase (JNK) activity using a Smad4 loss-of-function or gain-of-function analysis. Additionally, stable overexpression of Smad4 clearly affected the migration of human pancreatic epithelioid carcinoma PANC-1 cells, but did not affect cell growth. In addition, the present study revealed that upregulation of mitogen-activated protein kinase phosphatase-1 is required for the reduction of JNK activity by Smad4, leading to a decrease in vascular endothelial growth factor expression and inhibiting cell migration. Overall, the present findings indicate that Smad4 may suppress JNK activation and inhibit the tumor characteristics of pancreatic cancer cells.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Smad4 inhibits cell migration via suppression of JNK activity in human pancreatic carcinoma PANC-1 cells

Zhang¹,

Cao²,

Pei³

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Survival of treated elderly patients in Comorbid c., Comorbid conditions; SES, socioeconomic status; NOS, not otherwise specified; N, number of patients. 1 Region-wide data only n = 420 (18% of all patients). 2 excluding patients with unknown comorbid conditions.…”

Section: Discussionmentioning

confidence: 99%

Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer

Geest¹,

Mohammad²,

Besselink³

et al. 2017

European Journal of Cancer

View full text Add to dashboard Cite

Despite an aging population and underrepresentation of elderly patients in clinical trials, studies on elderly patients with metastatic pancreatic cancer are scarce. This study investigated the use of chemotherapy and survival in elderly patients with metastatic pancreatic cancer. From the Netherlands Cancer Registry, all 9407 patients diagnosed with primary metastatic pancreatic adenocarcinoma in 2005-2013 were selected to investigate chemotherapy use and overall survival (OS), using Kaplan-Meier and Cox proportional hazard regression analyses. Over time, chemotherapy use increased in all age groups (<70 years: from 26 to 43%, 70-74 years: 14 to 25%, 75-79 years: 5 to 13%, all P < 0.001, and ≥80 years: 2 to 3% P = 0.56). Median age of 2,180 patients who received chemotherapy was 63 years (range 21-86 years, 1.6% was ≥80 years). In chemotherapy-treated patients, with rising age (<70, 70-74, 75-79, ≥80 years), microscopic tumor verification occurred less frequently (91-88-87-77%, respectively, P = 0.009) and OS diminished (median 25-26-19-16 weeks, P = 0.003). After adjustment for confounding factors, worse survival of treated patients ≥75 years persisted. Despite limited chemotherapy use in elderly age, suggestive of strong selection, elderly patients (≥75 years) who received chemotherapy for metastatic pancreatic cancer exhibited a worse survival compared to younger patients receiving chemotherapy. Cancer Medicine Open Access 2841

show abstract

“…Most patients have inoperable disease at diagnosis, and survival for advanced disease is less than 5 % at 5 years [1,2]. The pivotal UK ABC-02 trial of gemcitabine alone or in combination with cisplatin confirmed significant survival advantage for the combination regimen [3].…”

mentioning

confidence: 97%

TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer

Ferraro

Goldstein

O’Connell

et al. 2016

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999–2007: Results of EUROCARE-5

Cited by 129 publications

References 24 publications

Smad4 inhibits cell migration via suppression of JNK activity in human pancreatic carcinoma PANC-1 cells

Smad4 inhibits cell migration via suppression of JNK activity in human pancreatic carcinoma PANC-1 cells

Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer

TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer

Contact Info

Product

Resources

About